Difference between revisions of "Amsacrine (Amsidine)"
Jump to navigation
Jump to search
m (categories) |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (20 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Synthetic acridine-derivate. Exact mechanism unclear; amsacrine binds to DNA by intercalation and external electrostatic binding, which inhibits DNA synthesis and causes DNA fragmentation.<ref name="insert">[http://www.nordmedica.com/fileadmin/user_upload/Pdf_filer/AMSIDINE_NL-EN.pdf Amsacrine (Amsidine) package insert]</ref><ref>[[ | + | Class/mechanism: Synthetic acridine-derivate. Exact mechanism unclear; amsacrine binds to DNA by intercalation and external electrostatic binding, which inhibits DNA synthesis and causes DNA fragmentation.<ref name="insert">[http://www.nordmedica.com/fileadmin/user_upload/Pdf_filer/AMSIDINE_NL-EN.pdf Amsacrine (Amsidine) package insert]</ref><ref>[[:File:Amsacrine.pdf | Amsacrine (Amsidine) package insert (locally hosted backup)]]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[vesicant]] | <br>Extravasation: [[vesicant]] | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== | ||
*[http://www.uptodate.com/contents/amsacrine-patient-drug-information Amsacrine (Amsidine) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/amsacrine-patient-drug-information Amsacrine (Amsidine) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/amsacrine-patient-drug-information Amsacrine (Amsidine) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/amsacrine-patient-drug-information Amsacrine (Amsidine) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Acute myeloid leukemia, pediatric]] | ||
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | *1982-04-23: EURD | ||
| + | ==Also known as== | ||
| + | *'''Code names:''' CI-880, SN-11841 | ||
| + | *'''Generic names:''' acridinyl anisidide, AMSA, Cain's acridine, m-AMSA | ||
| + | *'''Brand names:''' Amekrin, Amsa P-D, Amsidine, Amsidyl, Lamasine | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
| − | [[Category: | + | [[Category:Intravenous medications]] |
| − | [[Category:Vesicant | + | |
| + | [[Category:Vesicant]] | ||
| + | |||
| + | [[Category:Human DNA synthesis inhibitors]] | ||
| + | [[Category:Topoisomerase II inhibitors]] | ||
| + | |||
| + | [[Category:Acute myeloid leukemia medications (historic)]] | ||
| + | |||
| + | [[Category:EMA approved in 1982]] | ||
| + | [[Category:Health Canada approved drugs]] | ||
Latest revision as of 01:02, 29 June 2024
General information
Class/mechanism: Synthetic acridine-derivate. Exact mechanism unclear; amsacrine binds to DNA by intercalation and external electrostatic binding, which inhibits DNA synthesis and causes DNA fragmentation.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Patient drug information
Diseases for which it is used
History of changes in EMA indication
- 1982-04-23: EURD
Also known as
- Code names: CI-880, SN-11841
- Generic names: acridinyl anisidide, AMSA, Cain's acridine, m-AMSA
- Brand names: Amekrin, Amsa P-D, Amsidine, Amsidyl, Lamasine